Lilly predicts it will achieve an adjusted profit of between $23.00 and $23.70 per share this year, an increase on its ...

Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the ...

Asian shares have retreated after President Donald Trump's meeting with Chinese leader Xi Jinping. Trump said the meeting was ...

Novo Nordisk faces headwinds from regulatory uncertainty, competitive efficacy gaps with Eli Lilly and technical downward ...

Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.

Wall Street eyed a US-China truce agreed by Trump and Xi, cooling hopes for a December rate cut and the next batch of Big Tech earnings.

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the morning session after the ...

Revenue in Q3 2025 increased 54% to $17.60 billion driven by volume growth from Mounjaro and Zepbound. Q3 2025 EPS increased by $5.14 to $6.21 on a reported ...

Eli Lilly shares surged after strong third-quarter results and a raised annual forecast, powered by booming demand for its ...

The Big Pharma mainstay blew away EPS and revenue expectations when it reported Q3 financials, with management raising ...

Lilly now says it expects non-GAAP earnings from $23 to $23.70 a share this year, up from $21.75 to $23. The new guidance is ...